Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan
Tsuzuki et al.,
Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using..,
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.02.039 (date from earlier preprint)
Retrospective database analysis of 12,487 hospitalized patients in Japan, showing lower risk of oxygen requirement, but no significant difference in mortality or ventilation/ECMO.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 4.0% higher, HR 1.04, p = 0.21, treatment 69 of 824 (8.4%), control 285 of 11,663 (2.4%), adjusted per study, day 30.
|
risk of mechanical ventilation or ECMO, 1.7% lower, HR 0.98, p = 0.68, treatment 48 of 824 (5.8%), control 98 of 11,663 (0.8%), adjusted per study.
|
risk of progression, 15.0% lower, HR 0.85, p = 0.68, treatment 559 of 824 (67.8%), control 1,784 of 11,663 (15.3%), adjusted per study.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Tsuzuki et al., 10 Mar 2021, retrospective, Japan, peer-reviewed, 21 authors, average treatment delay 6.0 days.
Abstract: Journal Pre-proof
Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients
in Japan: A large observational study using the COVID-19 Registry
Japan
Shinya Tsuzuki , Kayoko Hayakawa , Yukari Uemura ,
Tomohiro Shinozaki , Nobuaki Matsunaga , Mari Terada ,
Setsuko Suzuki , Yusuke Asai , Koji Kitajima , Sho Saito ,
Gen Yamada , Taro Shibata , Masashi Kondo , Kazuo Izumi ,
Masayuki Hojo , Tetsuya Mizoue , Kazuhisa Yokota ,
Fukumi Nakamura-Uchiyama , Fumitake Saito , Wataru Sugiura ,
Norio Ohmagari
PII:
DOI:
Reference:
S1201-9712(22)00118-7
https://doi.org/10.1016/j.ijid.2022.02.039
IJID 6030
To appear in:
International Journal of Infectious Diseases
Received date:
Revised date:
Accepted date:
17 January 2022
15 February 2022
17 February 2022
Please
cite
this
article
as:
Shinya Tsuzuki ,
Kayoko Hayakawa ,
Yukari Uemura ,
Tomohiro Shinozaki ,
Nobuaki Matsunaga ,
Mari Terada ,
Setsuko Suzuki ,
Yusuke Asai ,
Koji Kitajima ,
Sho Saito ,
Gen Yamada ,
Taro Shibata ,
Masashi Kondo ,
Kazuo Izumi ,
Masayuki Hojo ,
Tetsuya Mizoue ,
Kazuhisa Yokota ,
Fukumi Nakamura-Uchiyama ,
Fumitake Saito , Wataru Sugiura , Norio Ohmagari , Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan,
International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.02.039
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A
large observational study using the COVID-19 Registry Japan
Shinya Tsuzukia,b,*, Kayoko Hayakawaa,c, Yukari Uemurad, Tomohiro Shinozakie,
Nobuaki Matsunagaa, Mari Teradac,d, Setsuko Suzukic, Yusuke Asaia, Koji Kitajimad,
Sho Saitoc, Gen Yamadac, Taro Shibataf, Masashi Kondog, Kazuo Izumid, Masayuki
Hojoh, Tetsuya Mizouei, Kazuhisa Yokotaj, Fukumi Nakamura-Uchiyamak, Fumitake
Saitol, Wataru Sugiurad, Norio Ohmagaria,c
a
AMR Clinical Reference Center, National Center for Global Health and Medicine,
Tokyo, Japan
b
c
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
Disease Control and Prevention Center, National Center for Global Health and
Medicine, Tokyo, Japan
d
Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo,
Japan
e
Department of Information and Computer Technology, Faculty of Engineering, Tokyo
University of Science, Tokyo, Japan
f
Biostatistics Division, Center for Research Administration and Support, National
Cancer Center, Tokyo, Japan
1
g
Center for Clinical Trial and Research Support, Fujita Health University, Aichi, Japan
h
Department of Respiratory Medicine, National Center for Global Health and Medicine,
Tokyo, Japan
i
Department of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit